<DOC>
	<DOCNO>NCT00088400</DOCNO>
	<brief_summary>Study Objectives : Primary Objective : To evaluate efficacy intratumoral/interstitial therapy TransMID compare best standard care patient progressive and/or recurrent , non-resectable glioblastoma multiforme . Secondary Objectives : To assess safety intratumoral/interstitial therapy TransMID compare best standard care patient progressive and/or recurrent , non-resectable glioblastoma multiforme . To evaluate possible difference efficacy and/or safety TransMID associate differ degree transferrin receptor expression tumor tissue serum anti-diphtheria toxin antibody titer level . Study Design : Multicenter , open label , randomize study compare TransMID chemotherapeutic regimen consider best standard care consist either nitrosureas , platinum compound , temozolomide , procarbazine PCV ( procarbazine , lomustine ( CCNU ) &amp; vincristine ) . A planned interim analysis primary efficacy endpoint conduct approximately 50 percent require event observe .</brief_summary>
	<brief_title>Comparison TransMID vs Standard Treatment Cancerous Brain Tumors</brief_title>
	<detailed_description>Study Objectives : Primary Objective : To evaluate efficacy intratumoral/interstitial therapy TransMID compare best standard care patient progressive and/or recurrent , non-resectable glioblastoma multiforme . Secondary Objectives : To assess safety intratumoral/interstitial therapy TransMID compare best standard care patient progressive and/or recurrent , non-resectable glioblastoma multiforme . To evaluate possible difference efficacy and/or safety TransMID associate differ degree transferrin receptor expression tumor tissue serum anti-diphtheria toxin antibody titer level . Study Design : Multicenter , open label , randomize study compare TransMID chemotherapeutic regimen consider best standard care consist either nitrosureas , platinum compound , temozolomide , procarbazine PCV ( procarbazine , lomustine ( CCNU ) &amp; vincristine ) . A planned interim analysis primary efficacy endpoint conduct approximately 50 percent require event observe .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients include study meet follow criterion : 1 . Male female least 18 year age . 2 . Histological result confirm GBM available . 3 . Progressive GBM ( great equal 25 percent increase contrast enhance tumor CSA compare nadir small previous measure CSA ) and/or recurrent GBM conventional treatment , include surgery ( biopsy debulking surgery ) and/or radiation therapy and/or chemotherapy . 4 . Prestudy MRIs use determine current progression and/or recurrence GBM available Investigator independent confirmation progression and/or recurrence . 5 . Patient consider candidate resection . 6 . If female childbearing potential , reliable method contraception must combine negative pregnancy test enter study ( female patient must willing use contraception 2 month last treatment TransMID ( Trademark ) ) . Male patient must willing use barrier method contraception 2 month last treatment TransMID ( Trademark ) 7 . Able willing follow instruction comply protocol . 8 . Provide write informed consent prior participation study . 9 . Karnofsky Performance Scale Score 70100 . 10 . Tumor characteristic : ) must unifocal ; ii ) must unilateral supratentorial ; iii ) lesion must diameter ( contrastenhanced MRI ) great equal 1.0 cm less equal 4.0 cm . EXCLUSION CRITERIA : Patients exclude study meet follow criterion : 1 . Anticipated life expectancy le 3 month . 2 . Infratentorial intraventricular tumor . 3 . Presence satellite tumor . 4 . Chemotherapy within 30 day prior study entry nitrosureas MitomycinC contain therapy within 42 day prior study entry . 5 . Radiotherapy stereotactic ( gamma knife ) radiosurgery within 90 day prior study entry . 6 . Tumor surgery , tumor debulking neurosurgery within 30 day prior study entry . 7 . Previous administration TransMID ( Trademark ) 8 . Previous enrollment study . 9 . Regional therapy include administration biodegradable polymer wafer contain carmustine within 90 day prior study entry brachytherapy within 12 calendar month prior study entry . 10 . Significant liver function impairment ( total bilirubin great 2.0 mg/dl 34.2 mircomol/L ; AST ALT great 3 time upper limit normal ) . 11 . Significant renal impairment ( serum creatinine great 1.7 mg/dL 150 micromol/L ) . 12 . Coagulopathy ( prothrombin time [ PT ] activate partial thromboplastin time [ APTT ] great 1.5 time control ) . 13 . Thrombocytopenia ( platelet count le 100 x 10 ( 3 ) /microL 100 x 10 ( 9 ) /L ) . 14 . Granulocytopenia ( absolute neutrophil count ( ANC ) , less 1 x 10 ( 3 ) /microL 1.0 x 10 ( 9 ) /L ) . 15 . Severe acute infection . 16 . Medical condition consider unacceptable anesthetic risk . 17 . Evidence mass effect CT MRI 5 mm midline shift and/or nausea , vomiting , reduce level consciousness clinically significant papilledema . 18 . Nursing pregnant female . A pregnancy test perform female childbearing potential . 19 . Use investigational product and/or participation another clinical research study within last 30 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Transferrin</keyword>
	<keyword>Brain Tumor</keyword>
	<keyword>Convection</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Targeted Protein Toxin</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>GBM</keyword>
</DOC>